Immunocore Holdings plc American Depositary Shares
IMCR Real Time Price USDRecent trades of IMCR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in IMCR holdings by institutional investors
Quarterly net insider trading by IMCR's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$50,000 Oct 20, 2023 Issue: Health Issues
IMCR Estimated quarterly lobbying spending
IMCR Revenue by Segment or Geography
New IMCR patent grants
-
Patent Title: Binding molecules Jan. 14, 2025
-
Patent Title: Binding molecules Nov. 05, 2024
-
Patent Title: Hiv specific binding molecules Oct. 01, 2024
-
Patent Title: T cell receptors and fusion proteins thereof Aug. 20, 2024
-
Patent Title: T cell receptors Jun. 25, 2024
-
Patent Title: Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex Mar. 12, 2024
-
Patent Title: Dosing regimen for gp100-specific tcr—anti-cd3 scfv fusion protein Nov. 28, 2023
-
Patent Title: Tcr libraries Aug. 29, 2023
-
Patent Title: Tcr libraries Aug. 29, 2023
-
Patent Title: T cell receptors Aug. 08, 2023
-
Patent Title: T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex May. 02, 2023
-
Patent Title: T cell receptors Nov. 22, 2022
-
Patent Title: Engineered immune-mobilizing t-cell receptors with enhanced affinity for hiv-1 gag Sep. 13, 2022
-
Patent Title: T cell receptors Aug. 30, 2022
-
Patent Title: Tcr libraries Oct. 05, 2021
-
Patent Title: Tcr libraries Sep. 21, 2021
-
Patent Title: Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex May. 25, 2021
-
Patent Title: Peptides derived from transient receptor potential cation channel subfamily m member 1 (trpm1), complexes comprising such peptides bound to mhc molecules Apr. 20, 2021
-
Patent Title: Peptides derived from transient receptor potential cation channel subfamily m member 1 (trpm1), complexes comprising such peptides bound to mhc molecules Mar. 16, 2021
-
Patent Title: Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex Mar. 02, 2021
-
Patent Title: Peptides derived from lengsin (lgsn), complexes comprising such peptides bound to mhc molecules Dec. 01, 2020
-
Patent Title: Peptides derived from kita-kyushu lung cancer antigen (kklc1, ct83, cxorf61) and complexes comprising such peptides bound to mhc molecules Nov. 17, 2020
-
Patent Title: Peptides derived from actin-like protein 8 (actl8) Oct. 06, 2020
-
Patent Title: Bifunctional polypeptides Mar. 03, 2020
-
Patent Title: Bifunctional polypeptides Dec. 31, 2019
-
Patent Title: Bifunctional polypeptides Sep. 24, 2019
-
Patent Title: Bifunctional polypeptides Nov. 20, 2018
-
Patent Title: High affinity hiv t cell receptors Feb. 09, 2016
-
Patent Title: Cells expressing modified t cell receptor Aug. 25, 2015
-
Patent Title: Nucleic acid molecules encoding non-naturally occurring t cell receptors and cells thereof Jun. 30, 2015
-
Patent Title: T cell receptor display Jun. 03, 2014
-
Patent Title: Non-naturally occurring t cell receptors Aug. 27, 2013
-
Patent Title: High affinity hiv t cell receptors Feb. 19, 2013
-
Patent Title: High affinity ny-eso t cell receptors Feb. 05, 2013
-
Patent Title: Cells expressing a modified t cell receptor Jan. 29, 2013
-
Patent Title: T cell receptor mutants Oct. 09, 2012
-
Patent Title: High affinity melan-a t cell receptors Jul. 10, 2012
-
Patent Title: High affinity ny-eso t cell receptor Mar. 27, 2012
-
Patent Title: T cell receptors which specifically bind to vygfvracl-hla-a24 Sep. 13, 2011
-
Patent Title: High affinity ny-eso t cell receptors Aug. 30, 2011
-
Patent Title: Soluble t cell receptors Jul. 27, 2010
-
Patent Title: Modified soluble t cell receptor Feb. 23, 2010
Federal grants, loans, and purchases
- $0 2025-04-09 00:00:00 Agency: Department of Veterans Affairs
- $44,179 2025-04-08 00:00:00 Agency: Department of Veterans Affairs
- $29,453 2025-03-14 00:00:00 Agency: Department of Veterans Affairs
- $88,802 2025-03-07 00:00:00 Agency: Department of Veterans Affairs
- $44,179 2025-02-14 00:00:00 Agency: Department of Veterans Affairs
- $14,800 2025-02-11 00:00:00 Agency: Department of Veterans Affairs
- $14,800 2025-01-31 00:00:00 Agency: Department of Veterans Affairs
- $88,802 2025-01-17 00:00:00 Agency: Department of Veterans Affairs
- $14,448 2024-12-19 00:00:00 Agency: Department of Veterans Affairs
- $86,687 2024-12-02 00:00:00 Agency: Department of Veterans Affairs
- $86,687 2024-10-11 00:00:00 Agency: Department of Veterans Affairs
- $28,896 2024-09-12 00:00:00 Agency: Department of Veterans Affairs
- $115,583 2024-07-03 00:00:00 Agency: Department of Veterans Affairs
- $0 2023-11-09 00:00:00 Agency: Department of Veterans Affairs
Estimated quarterly amount awarded to IMCR from public contracts
Recent insights relating to IMCR
Recent picks made for IMCR stock on CNBC
ETFs with the largest estimated holdings in IMCR
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $IMCR stock a Buy, Sell, or Hold?
- What is the price target for $IMCR stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $IMCR stock?
- Who owns the most shares of $IMCR stock?
- What funds own $IMCR stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IMCR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
- Address Oxfordshire, X0
- Market Cap 1.9 billion
- Employees 493
- Industrial Classification Biological Products, (No Disgnostic Substances)